Abstract CT183: Initial results from a phase 1a/1b study of STK-012, a first-in-class α/β IL-2 receptor biased partial agonist in advanced solid tumors (NCT05098132)Benjamin Izar,Dmitriy Zamarin,David R. Spigel, Christopher J. Hoimes,David F. McDermott,Kartik Sehgal,Yana G. Najjar,Adam J. Schoenfeld,Edward B. Garon,Ryan J. Sullivan,Brian S. Henick,Ticiana A. Leal,Michael E. Hurwitz,Rana R. McKay,Natalie Busby,Anita Mehta-Damani,Alex Azrilevich,Tony Tran,Naiyer Rizvi,Martin Oft,Alexander I. SpiraCancer Research（2024）引用 0|浏览38AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
